Impact of Vascular Resection on Survival and Postoperative Outcomes in Patients With Hilar Cholangiocarcinoma: A Retrospective Study

N/ANot Yet RecruitingNCT07311798

Yongjun Chen300 enrolled

Overview

Hilar cholangiocarcinoma is a highly aggressive malignancy, and surgical resection remains the only potentially curative treatment. Due to the frequent involvement of major vascular structures, vascular resection is increasingly performed to achieve negative surgical margins; however, its impact on survival and postoperative outcomes remains controversial. This retrospective study aims to evaluate the association between vascular resection and clinical outcomes, including survival and postoperative outcomes, in patients with hilar cholangiocarcinoma undergoing curative-intent surgery.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Cholangiocarcinoma, Hilar

Interventions

No Intervention: Observational CohortOTHER

This is an observational study. No intervention is assigned.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who underwent surgical treatment at the Department of Hepatobiliary and Pancreatic Surgery of our hospital between January 2010 and December 2024, including those with or without concomitant vascular resection. * Pathologically confirmed diagnosis of hilar cholangiocarcinoma after surgery. * Complete clinical and follow-up data available for outcome analysis. Exclusion Criteria: * Patients with distant metastasis or who underwent only palliative or exploratory surgery. * Patients diagnosed preoperatively or intraoperatively with other types of biliary malignancies not located at the hilar region. * Patients with incomplete medical records or missing key clinical or follow-up data.

Outcomes

Primary Outcomes

Postoperative Complications Grade II or Higher (Clavien-Dindo ≥ II)

Postoperative complications within 30 days after surgery will be assessed and classified according to the Clavien-Dindo classification system. Grade II or higher complications are defined as complications requiring pharmacological treatment, blood transfusion, interventional procedures, reoperation, intensive care management, or resulting in death.

Time frame: Within 30 days after surgery

Overall Survival (OS)

Time from the date of curative-intent surgery to death from any cause or last follow-up. Patients who are alive at the last follow-up will be censored. Survival data will be collected from medical records and follow-up visits.

Time frame: From surgery to death or last follow-up (up to 5 years)

Secondary Outcomes

Perioperative Mortality

Death occurring within 30 days after surgery or during the index hospitalization, whichever occurs later.

Time frame: 30 days after surgery or during hospitalization

Length of Postoperative Hospital Stay

Number of days from the date of surgery to hospital discharge.

Time frame: From the date of surgery to hospital discharge, assessed up to 90 days.

Intraoperative Blood Loss

Estimated blood loss recorded in the operative report, measured in milliliters.

Time frame: During surgery

Disease-Free Survival (DFS)

Time from surgery to tumor recurrence, metastasis, death from any cause, or last follow-up, whichever occurs first.

Time frame: From surgery to tumor recurrence, metastasis, death, or last follow-up (up to 5 years)